Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-trace').style.display = (document.getElementById('cakeErr6801429168900-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801429168900-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-code').style.display = (document.getElementById('cakeErr6801429168900-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-context').style.display = (document.getElementById('cakeErr6801429168900-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801429168900-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801429168900-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 32045,
		&#039;title&#039; =&gt; &#039;Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Hindustan Times&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;
&lt;br /&gt;
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;
&lt;br /&gt;
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;
&lt;br /&gt;
In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;
&lt;br /&gt;
WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;
&lt;br /&gt;
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;
&lt;br /&gt;
It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;
&lt;br /&gt;
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;
&lt;br /&gt;
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;
&lt;br /&gt;
Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4680121,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 32045,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Hindustan Times

India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Hindustan Times&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;&lt;br /&gt;Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;&lt;br /&gt;In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;&lt;br /&gt;Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;&lt;br /&gt;In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;&lt;br /&gt;WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;&lt;br /&gt;Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;&lt;br /&gt;It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;&lt;br /&gt;Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;&lt;br /&gt;Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;&lt;br /&gt;Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 32045,
	&#039;title&#039; =&gt; &#039;Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Hindustan Times&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;
&lt;br /&gt;
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;
&lt;br /&gt;
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;
&lt;br /&gt;
In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;
&lt;br /&gt;
WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;
&lt;br /&gt;
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;
&lt;br /&gt;
It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;
&lt;br /&gt;
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;
&lt;br /&gt;
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;
&lt;br /&gt;
Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4680121,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 32045
$metaTitle = &#039;LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;
$metaKeywords = &#039;generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C&#039;
$metaDesc = &#039;
-Hindustan Times

India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Hindustan Times&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;&lt;br /&gt;Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;&lt;br /&gt;In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;&lt;br /&gt;Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;&lt;br /&gt;In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;&lt;br /&gt;WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;&lt;br /&gt;Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;&lt;br /&gt;It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;&lt;br /&gt;Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;&lt;br /&gt;Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;&lt;br /&gt;Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna | Im4change.org</title>
    <meta name="description" content="
-Hindustan Times

India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Hindustan Times<br /><br />India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br /><br />Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br /><br />&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br /><br />In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br /><br />Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br /><br />In India, 12 to 18 million people are infected by the disease.<br /><br />WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br /><br />&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br /><br />Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br /><br />It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br /><br />Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br /><br />Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br /><br />Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-trace').style.display = (document.getElementById('cakeErr6801429168900-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801429168900-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-code').style.display = (document.getElementById('cakeErr6801429168900-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-context').style.display = (document.getElementById('cakeErr6801429168900-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801429168900-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801429168900-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 32045,
		&#039;title&#039; =&gt; &#039;Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Hindustan Times&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;
&lt;br /&gt;
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;
&lt;br /&gt;
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;
&lt;br /&gt;
In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;
&lt;br /&gt;
WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;
&lt;br /&gt;
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;
&lt;br /&gt;
It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;
&lt;br /&gt;
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;
&lt;br /&gt;
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;
&lt;br /&gt;
Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4680121,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 32045,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Hindustan Times

India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Hindustan Times&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;&lt;br /&gt;Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;&lt;br /&gt;In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;&lt;br /&gt;Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;&lt;br /&gt;In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;&lt;br /&gt;WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;&lt;br /&gt;Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;&lt;br /&gt;It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;&lt;br /&gt;Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;&lt;br /&gt;Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;&lt;br /&gt;Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 32045,
	&#039;title&#039; =&gt; &#039;Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Hindustan Times&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;
&lt;br /&gt;
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;
&lt;br /&gt;
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;
&lt;br /&gt;
In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;
&lt;br /&gt;
WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;
&lt;br /&gt;
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;
&lt;br /&gt;
It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;
&lt;br /&gt;
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;
&lt;br /&gt;
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;
&lt;br /&gt;
Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4680121,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 32045
$metaTitle = &#039;LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;
$metaKeywords = &#039;generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C&#039;
$metaDesc = &#039;
-Hindustan Times

India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Hindustan Times&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;&lt;br /&gt;Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;&lt;br /&gt;In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;&lt;br /&gt;Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;&lt;br /&gt;In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;&lt;br /&gt;WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;&lt;br /&gt;Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;&lt;br /&gt;It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;&lt;br /&gt;Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;&lt;br /&gt;Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;&lt;br /&gt;Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna | Im4change.org</title>
    <meta name="description" content="
-Hindustan Times

India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Hindustan Times<br /><br />India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br /><br />Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br /><br />&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br /><br />In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br /><br />Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br /><br />In India, 12 to 18 million people are infected by the disease.<br /><br />WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br /><br />&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br /><br />Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br /><br />It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br /><br />Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br /><br />Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br /><br />Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-trace').style.display = (document.getElementById('cakeErr6801429168900-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801429168900-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-code').style.display = (document.getElementById('cakeErr6801429168900-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801429168900-context').style.display = (document.getElementById('cakeErr6801429168900-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801429168900-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801429168900-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 32045,
		&#039;title&#039; =&gt; &#039;Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Hindustan Times&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;
&lt;br /&gt;
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;
&lt;br /&gt;
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;
&lt;br /&gt;
In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;
&lt;br /&gt;
WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;
&lt;br /&gt;
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;
&lt;br /&gt;
It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;
&lt;br /&gt;
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;
&lt;br /&gt;
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;
&lt;br /&gt;
Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4680121,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 32045,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Hindustan Times

India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Hindustan Times&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;&lt;br /&gt;Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;&lt;br /&gt;In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;&lt;br /&gt;Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;&lt;br /&gt;In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;&lt;br /&gt;WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;&lt;br /&gt;Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;&lt;br /&gt;It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;&lt;br /&gt;Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;&lt;br /&gt;Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;&lt;br /&gt;Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 32045,
	&#039;title&#039; =&gt; &#039;Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Hindustan Times&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;
&lt;br /&gt;
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;
&lt;br /&gt;
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;
&lt;br /&gt;
In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;
&lt;br /&gt;
WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;
&lt;br /&gt;
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;
&lt;br /&gt;
It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;
&lt;br /&gt;
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;
&lt;br /&gt;
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;
&lt;br /&gt;
Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4680121,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 32045
$metaTitle = &#039;LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna&#039;
$metaKeywords = &#039;generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C&#039;
$metaDesc = &#039;
-Hindustan Times

India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Hindustan Times&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&amp;rsquo;s patent application was rejected in January 2015.&lt;br /&gt;&lt;br /&gt;Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&amp;rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .&lt;br /&gt;&lt;br /&gt;In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.&lt;br /&gt;&lt;br /&gt;Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.&lt;br /&gt;&lt;br /&gt;In India, 12 to 18 million people are infected by the disease.&lt;br /&gt;&lt;br /&gt;WHO, which has sought fairer pricing of &amp;lsquo;unaffordable&amp;rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&amp;rdquo; WHO experts said.&lt;br /&gt;&lt;br /&gt;Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.&lt;br /&gt;&lt;br /&gt;It would amount to 10.5% of Netherlands&amp;rsquo; annual drug budget, 190% for Poland, and 33% for the UK.&lt;br /&gt;&lt;br /&gt;Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.&lt;br /&gt;&lt;br /&gt;Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.&lt;br /&gt;&lt;br /&gt;Natco and Hetero got the Drugs Controller General of India&amp;rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna | Im4change.org</title>
    <meta name="description" content="
-Hindustan Times

India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Hindustan Times<br /><br />India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br /><br />Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br /><br />&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br /><br />In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br /><br />Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br /><br />In India, 12 to 18 million people are infected by the disease.<br /><br />WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br /><br />&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br /><br />Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br /><br />It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br /><br />Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br /><br />Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br /><br />Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 32045,
		'title' => 'Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna',
		'subheading' => '',
		'description' => '<div align="justify">
-Hindustan Times<br />
<br />
India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br />
<br />
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br />
<br />
&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br />
<br />
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br />
<br />
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br />
<br />
In India, 12 to 18 million people are infected by the disease.<br />
<br />
WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br />
<br />
&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br />
<br />
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br />
<br />
It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br />
<br />
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br />
<br />
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br />
<br />
Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
</div>',
		'credit_writer' => 'Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4680121,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 32045,
	'metaTitle' => 'LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna',
	'metaKeywords' => 'generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C',
	'metaDesc' => '
-Hindustan Times

India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...',
	'disp' => '<div align="justify">-Hindustan Times<br /><br />India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br /><br />Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br /><br />&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br /><br />In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br /><br />Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br /><br />In India, 12 to 18 million people are infected by the disease.<br /><br />WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br /><br />&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br /><br />Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br /><br />It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br /><br />Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br /><br />Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br /><br />Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 32045,
	'title' => 'Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna',
	'subheading' => '',
	'description' => '<div align="justify">
-Hindustan Times<br />
<br />
India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br />
<br />
Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br />
<br />
&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br />
<br />
In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br />
<br />
Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br />
<br />
In India, 12 to 18 million people are infected by the disease.<br />
<br />
WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br />
<br />
&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br />
<br />
Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br />
<br />
It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br />
<br />
Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br />
<br />
Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br />
<br />
Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.
</div>',
	'credit_writer' => 'Hindustan Times, 10 September, 2016, http://www.hindustantimes.com/business-newspaper/indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who/story-R7txVobNv7jLTqIO2DGZEK.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'indian-generics-bringing-down-global-price-of-hepatitis-c-drugs-finds-who-himani-chandna-4680121',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4680121,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 32045
$metaTitle = 'LATEST NEWS UPDATES | Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna'
$metaKeywords = 'generic drugs,generic medicine,generic medicines,Access to Medicines,Hepatitis C'
$metaDesc = '
-Hindustan Times

India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.

Thanks to domestic drugmakers, the world is looking to India to reduce the price...'
$disp = '<div align="justify">-Hindustan Times<br /><br />India&rsquo;s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc&rsquo;s patent application was rejected in January 2015.<br /><br />Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further.<br /><br />&ldquo;By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,&rdquo; said Henk Bekedam, World Health Organisation (WHO) representative in India .<br /><br />In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively.<br /><br />Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure.<br /><br />In India, 12 to 18 million people are infected by the disease.<br /><br />WHO, which has sought fairer pricing of &lsquo;unaffordable&rsquo; hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs.<br /><br />&ldquo;No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,&rdquo; WHO experts said.<br /><br />Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries.<br /><br />It would amount to 10.5% of Netherlands&rsquo; annual drug budget, 190% for Poland, and 33% for the UK.<br /><br />Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment.<br /><br />Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people.<br /><br />Natco and Hetero got the Drugs Controller General of India&rsquo;s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Indian generics bringing down global price of hepatitis C drugs, finds WHO -Himani Chandna

-Hindustan Times India’s generic drug manufacturers have flooded the market with cheaper medicines to treat hepatitis C after Gilead Sciences Inc’s patent application was rejected in January 2015. Thanks to domestic drugmakers, the world is looking to India to reduce the price of hepatitis C drug further. “By scaling up the production of generic medicines, India is playing a pivotal role globally in reducing the prices of medicines for hepatitis C,” said Henk Bekedam, World Health Organisation (WHO) representative in India . In Japan, one tablet of sofosbuvir costs Rs 30,000 and in India Rs 350, daclatasvir costs Rs 10,000 and Rs 135, and the combination drug of sofosbuvir and ledipasvir costs Rs 40,000 and Rs 500, respectively. Sofosbuvir, daclatasvir, and ledipasvir are generic names of drugs used to treat hepatitis C. The virus can lead to cirrhosis, liver cancer, and liver failure. In India, 12 to 18 million people are infected by the disease. WHO, which has sought fairer pricing of ‘unaffordable’ hepatitis C medicines in western nations, has lauded Indian drug makers for producing cheap drugs. “No country in the world can afford to treat every patient, who has the potentially fatal liver disease hepatitis C, using new (patented) drugs that cure the condition,” WHO experts said. Their investigation shows the drug treatment (using patented drugs) of all patients would be very expensive for countries. It would amount to 10.5% of Netherlands’ annual drug budget, 190% for Poland, and 33% for the UK. Some states, including Punjab, have negotiated with Indian generic companies and got the antivirals for $300-370 for a 12-week treatment. Though the treatment is cheaper in India than that in the US or the UK, it is unaffordable for most people. Natco and Hetero got the Drugs Controller General of India’s approval to launch the combination of ledipasvir and sofosbuvir, and daclatasvir in the second week of December, while Strides Shasun was allowed to make sofosbuvir.